secwatch.observer — SEC 8-K summary
======================================

Issuer:     Nabriva Therapeutics plc (—)
CIK:        0001641640
Form:       8-K
Filed at:   2023-06-01T23:59:59+00:00
Accession:  0001104659-23-067071
Event type: regulatory
Sentiment:  negative
Materiality: 0.85
Item codes: 3.01
LLM model:  deepseek-v4-flash:cloud@v2

Nabriva receives Nasdaq delisting notice over negative equity of -$4.4M
-----------------------------------------------------------------------

- Stockholders' equity of -$4,357,000 as of March 31, 2023, below $2.5M minimum.
- Nasdaq letter received May 25, 2023; company has until July 10, 2023 to submit compliance plan.
- If plan accepted, extension of up to 180 days from May 25 may be granted.
- Alternative listing standards (market value or net income) not currently met.
- No immediate impact on listing but delisting risk if compliance not regained.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1641640/000110465923067071/0001104659-23-067071-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1641640/000110465923067071/tm2317450d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-067071

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer